Overview

Diffusion Basis Spectrum Imaging (DBSI) represents a potential leap forward in improving prostate cancer early detection: a non-invasive and accurate imaging test for clinically significant prostate cancer.

Eligibility

Inclusion Criteria:

• Over 18 years of age and willing and able to provide informed consent.
• Patients with no prior diagnosis of prostate cancer, who are planning to undergo prostate biopsy as clinical standard of care ("early detection cohort")
• Including those men with:
• an elevated PSA and no prior biopsy
• an elevated PSA and a negative prior biopsy
• Patients with a prior diagnosis of prostate cancer, who are currently managed with active surveillance, who are planning to undergo biopsy as clinical standard of care ("active surveillance cohort")

Exclusion Criteria:

• Patients with any clinical contraindication to MRI

*Including but not limited to:

• Those with metallic implants, such as pacemakers or implantable cardioverter-defibrillators
• Those with cochlear implants
• Those with claustrophobia
• Those who cannot lie flat for over 1 hour
• Patients with prior prostate surgery (e.g. radical prostatectomy, TURP)